230 related articles for article (PubMed ID: 25922907)
1. Effect of BRAF mutational status on expression profiles in conventional papillary thyroid carcinomas.
Schulten HJ; Alotibi R; Al-Ahmadi A; Ata M; Karim S; Huwait E; Gari M; Al-Ghamdi K; Al-Mashat F; Al-Hamour O; Al-Qahtani MH; Al-Maghrabi J
BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S6. PubMed ID: 25922907
[TBL] [Abstract][Full Text] [Related]
2. Comparison of microarray expression profiles between follicular variant of papillary thyroid carcinomas and follicular adenomas of the thyroid.
Schulten HJ; Al-Mansouri Z; Baghallab I; Bagatian N; Subhi O; Karim S; Al-Aradati H; Al-Mutawa A; Johary A; Meccawy AA; Al-Ghamdi K; Al-Hamour O; Al-Qahtani MH; Al-Maghrabi J
BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S7. PubMed ID: 25923053
[TBL] [Abstract][Full Text] [Related]
3. Reduced expression of THRβ in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression.
Rosignolo F; Maggisano V; Sponziello M; Celano M; Di Gioia CR; D'Agostino M; Giacomelli L; Verrienti A; Dima M; Pecce V; Durante C
J Endocrinol Invest; 2015 Dec; 38(12):1283-9. PubMed ID: 26003825
[TBL] [Abstract][Full Text] [Related]
4. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
[TBL] [Abstract][Full Text] [Related]
5. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
[TBL] [Abstract][Full Text] [Related]
6. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.
Durante C; Puxeddu E; Ferretti E; Morisi R; Moretti S; Bruno R; Barbi F; Avenia N; Scipioni A; Verrienti A; Tosi E; Cavaliere A; Gulino A; Filetti S; Russo D
J Clin Endocrinol Metab; 2007 Jul; 92(7):2840-3. PubMed ID: 17488796
[TBL] [Abstract][Full Text] [Related]
7. Role of BRAF and RAS Mutations in Extrathyroidal Extension in Papillary Thyroid Cancer.
Park JY; Yi JW; Park CH; Lim Y; Lee KH; Lee KE; Kim JH
Cancer Genomics Proteomics; 2016; 13(2):171-81. PubMed ID: 26912807
[TBL] [Abstract][Full Text] [Related]
8. High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas.
de Biase D; Cesari V; Visani M; Casadei GP; Cremonini N; Gandolfi G; Sancisi V; Ragazzi M; Pession A; Ciarrocchi A; Tallini G
J Clin Endocrinol Metab; 2014 Aug; 99(8):E1530-8. PubMed ID: 24780046
[TBL] [Abstract][Full Text] [Related]
9. BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas.
Durante C; Tallini G; Puxeddu E; Sponziello M; Moretti S; Ligorio C; Cavaliere A; Rhoden KJ; Verrienti A; Maranghi M; Giacomelli L; Russo D; Filetti S
Eur J Endocrinol; 2011 Sep; 165(3):455-63. PubMed ID: 21653734
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of miR-221 is associated with aggressive clinicopathologic characteristics and the BRAF mutation in papillary thyroid carcinomas.
Zhou YL; Liu C; Dai XX; Zhang XH; Wang OC
Med Oncol; 2012 Dec; 29(5):3360-6. PubMed ID: 22855362
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite stable colorectal cancers stratified by the BRAF V600E mutation show distinct patterns of chromosomal instability.
Bond CE; Nancarrow DJ; Wockner LF; Wallace L; Montgomery GW; Leggett BA; Whitehall VL
PLoS One; 2014; 9(3):e91739. PubMed ID: 24651849
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profile analyze the molecular mechanism of CXCR7 regulating papillary thyroid carcinoma growth and metastasis.
Zhang H; Teng X; Liu Z; Zhang L; Liu Z
J Exp Clin Cancer Res; 2015 Feb; 34(1):16. PubMed ID: 25887589
[TBL] [Abstract][Full Text] [Related]
13. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
14. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
Guerra A; Zeppa P; Bifulco M; Vitale M
Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
[TBL] [Abstract][Full Text] [Related]
15. ERK phosphorylation is not increased in papillary thyroid carcinomas with BRAF(V600E) mutation compared to that of corresponding normal thyroid tissues.
Kim SW; Kim HK; Lee JI; Jang HW; Choe JH; Kim JH; Kim JS; Hur KY; Kim JH; Chung JH
Endocr Res; 2013; 38(2):89-97. PubMed ID: 23544999
[TBL] [Abstract][Full Text] [Related]
16. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis.
Giordano TJ; Kuick R; Thomas DG; Misek DE; Vinco M; Sanders D; Zhu Z; Ciampi R; Roh M; Shedden K; Gauger P; Doherty G; Thompson NW; Hanash S; Koenig RJ; Nikiforov YE
Oncogene; 2005 Oct; 24(44):6646-56. PubMed ID: 16007166
[TBL] [Abstract][Full Text] [Related]
17. Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas.
Rodrigues R; Roque L; Espadinha C; Pinto A; Domingues R; Dinis J; Catarino A; Pereira T; Leite V
Oncol Rep; 2007 Oct; 18(4):917-26. PubMed ID: 17786355
[TBL] [Abstract][Full Text] [Related]
18. Multicentric occurrence of multiple papillary thyroid carcinomas--HUMARA and BRAF mutation analysis.
Nakazawa T; Kondo T; Tahara I; Kasai K; Inoue T; Oishi N; Mochizuki K; Kubota T; Katoh R
Cancer Med; 2015 Aug; 4(8):1272-80. PubMed ID: 25882744
[TBL] [Abstract][Full Text] [Related]
19. Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas.
Yoon M; Jung SJ; Kim TH; Ha TK; Urm SH; Park JS; Lee SM; Bae SK
Endocr Res; 2016; 41(1):64-9. PubMed ID: 26513490
[TBL] [Abstract][Full Text] [Related]
20. Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.
Gandolfi G; Sancisi V; Torricelli F; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A
J Clin Endocrinol Metab; 2013 May; 98(5):E934-42. PubMed ID: 23533235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
